S&P 500   3,456.62 (+0.61%)
DOW   28,405.87 (+0.69%)
QQQ   284.30 (+0.04%)
AAPL   115.46 (-1.21%)
MSFT   214.88 (+0.04%)
FB   278.07 (-0.24%)
GOOGL   1,608.75 (+1.44%)
AMZN   3,172.18 (-0.40%)
TSLA   429.73 (+1.68%)
NVDA   536.12 (-0.90%)
BABA   306.50 (-0.48%)
CGC   20.04 (+2.82%)
GE   7.69 (+5.05%)
MU   54.74 (+2.68%)
AMD   79.82 (+0.78%)
T   28.28 (+5.84%)
F   8.14 (+3.69%)
ACB   4.76 (-1.86%)
GILD   60.19 (-0.03%)
NFLX   484.60 (-0.91%)
BA   168.58 (+2.88%)
NIO   27.28 (-2.08%)
DIS   127.74 (+0.88%)
S&P 500   3,456.62 (+0.61%)
DOW   28,405.87 (+0.69%)
QQQ   284.30 (+0.04%)
AAPL   115.46 (-1.21%)
MSFT   214.88 (+0.04%)
FB   278.07 (-0.24%)
GOOGL   1,608.75 (+1.44%)
AMZN   3,172.18 (-0.40%)
TSLA   429.73 (+1.68%)
NVDA   536.12 (-0.90%)
BABA   306.50 (-0.48%)
CGC   20.04 (+2.82%)
GE   7.69 (+5.05%)
MU   54.74 (+2.68%)
AMD   79.82 (+0.78%)
T   28.28 (+5.84%)
F   8.14 (+3.69%)
ACB   4.76 (-1.86%)
GILD   60.19 (-0.03%)
NFLX   484.60 (-0.91%)
BA   168.58 (+2.88%)
NIO   27.28 (-2.08%)
DIS   127.74 (+0.88%)
S&P 500   3,456.62 (+0.61%)
DOW   28,405.87 (+0.69%)
QQQ   284.30 (+0.04%)
AAPL   115.46 (-1.21%)
MSFT   214.88 (+0.04%)
FB   278.07 (-0.24%)
GOOGL   1,608.75 (+1.44%)
AMZN   3,172.18 (-0.40%)
TSLA   429.73 (+1.68%)
NVDA   536.12 (-0.90%)
BABA   306.50 (-0.48%)
CGC   20.04 (+2.82%)
GE   7.69 (+5.05%)
MU   54.74 (+2.68%)
AMD   79.82 (+0.78%)
T   28.28 (+5.84%)
F   8.14 (+3.69%)
ACB   4.76 (-1.86%)
GILD   60.19 (-0.03%)
NFLX   484.60 (-0.91%)
BA   168.58 (+2.88%)
NIO   27.28 (-2.08%)
DIS   127.74 (+0.88%)
S&P 500   3,456.62 (+0.61%)
DOW   28,405.87 (+0.69%)
QQQ   284.30 (+0.04%)
AAPL   115.46 (-1.21%)
MSFT   214.88 (+0.04%)
FB   278.07 (-0.24%)
GOOGL   1,608.75 (+1.44%)
AMZN   3,172.18 (-0.40%)
TSLA   429.73 (+1.68%)
NVDA   536.12 (-0.90%)
BABA   306.50 (-0.48%)
CGC   20.04 (+2.82%)
GE   7.69 (+5.05%)
MU   54.74 (+2.68%)
AMD   79.82 (+0.78%)
T   28.28 (+5.84%)
F   8.14 (+3.69%)
ACB   4.76 (-1.86%)
GILD   60.19 (-0.03%)
NFLX   484.60 (-0.91%)
BA   168.58 (+2.88%)
NIO   27.28 (-2.08%)
DIS   127.74 (+0.88%)
Log in
NASDAQ:SNGX

Soligenix Stock Forecast, Price & News

$1.70
+0.05 (+3.03 %)
(As of 10/22/2020 02:08 PM ET)
Add
Compare
Today's Range
$1.64
Now: $1.70
$2.47
50-Day Range
$1.70
MA: $1.83
$2.00
52-Week Range
$0.85
Now: $1.70
$3.54
Volume32,221 shs
Average Volume212,336 shs
Market Capitalization$50.75 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase 3 clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase 3 clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which is in Phase 1/2 clinical trial for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials; SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; and ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Read More
Soligenix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNGX
CUSIPN/A
Phone609-538-8200
Employees15

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.60 million
Book Value$0.07 per share

Profitability

Net Income$-9,360,000.00
Net Margins-477.38%

Miscellaneous

Market Cap$50.75 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$1.70
+0.05 (+3.03 %)
(As of 10/22/2020 02:08 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SNGX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Soligenix (NASDAQ:SNGX) Frequently Asked Questions

How has Soligenix's stock price been impacted by COVID-19 (Coronavirus)?

Soligenix's stock was trading at $2.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SNGX shares have decreased by 31.9% and is now trading at $1.73.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Soligenix?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soligenix in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Soligenix
.

When is Soligenix's next earnings date?

Soligenix is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Soligenix
.

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) issued its quarterly earnings data on Friday, August, 14th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.04. The biopharmaceutical company had revenue of $0.50 million for the quarter, compared to analysts' expectations of $1.10 million. Soligenix had a negative net margin of 477.38% and a negative return on equity of 468.27%.
View Soligenix's earnings history
.

What price target have analysts set for SNGX?

2 equities research analysts have issued twelve-month price targets for Soligenix's stock. Their forecasts range from $2.00 to $4.00. On average, they anticipate Soligenix's stock price to reach $3.00 in the next year. This suggests a possible upside of 73.4% from the stock's current price.
View analysts' price targets for Soligenix
.

Who are some of Soligenix's key competitors?

What other stocks do shareholders of Soligenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), Opko Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM).

Who are Soligenix's key executives?

Soligenix's management team includes the following people:
  • Dr. Christopher J. Schaber Ph.D., Chairman, CEO & Pres (Age 54, Pay $604.73k)
  • Mr. Jonathan L. Guarino CPA, CGMA, Sr. VP, CFO & Corp. Sec. (Age 48, Pay $242.65k)
  • Dr. Oreola Donini Ph.D., Sr. VP & Chief Scientific Officer (Age 48, Pay $293.94k)
  • Dr. Richard C. Straube M.D., MSc., Sr. VP & Chief Medical Officer (Age 68, Pay $256.08k)
  • Mr. Richard L. Dunning, Exec. Officer (Age 74)

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

Who are Soligenix's major shareholders?

Soligenix's stock is owned by many different institutional and retail investors. Top institutional shareholders include FNY Investment Advisers LLC (0.30%) and Wedbush Securities Inc. (0.08%). Company insiders that own Soligenix stock include Christopher J Schaber, Diane L Parks and Jerome B Zeldis.
View institutional ownership trends for Soligenix
.

Which major investors are buying Soligenix stock?

SNGX stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC, and Wedbush Securities Inc.. Company insiders that have bought Soligenix stock in the last two years include Christopher J Schaber, Diane L Parks, and Jerome B Zeldis.
View insider buying and selling activity for Soligenix
.

How do I buy shares of Soligenix?

Shares of SNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Soligenix's stock price today?

One share of SNGX stock can currently be purchased for approximately $1.73.

How big of a company is Soligenix?

Soligenix has a market capitalization of $51.64 million and generates $4.60 million in revenue each year. The biopharmaceutical company earns $-9,360,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. Soligenix employs 15 workers across the globe.

What is Soligenix's official website?

The official website for Soligenix is www.soligenix.com.

How can I contact Soligenix?

Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at 609-538-8200 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.